Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Reply to Comment on: Dopamine Transporter (DaT) Scan Utilization in a Movement Disorder Center.
Oravivattanakul S, Benchaya L, Ahmed A, Itin I, Cooper S, Gostkowski M, Rudolph J, Appleby K, Sweeney P, Fernandez HH, Wu G. Oravivattanakul S, et al. Among authors: appleby k. Mov Disord Clin Pract. 2016 Jul 28;4(1):155-156. doi: 10.1002/mdc3.12403. eCollection 2017 Jan-Feb. Mov Disord Clin Pract. 2016. PMID: 30713966 Free PMC article. No abstract available.
Dopamine Transporter (DaT) Scan Utilization in a Movement Disorder Center.
Oravivattanakul S, Benchaya L, Wu G, Ahmed A, Itin I, Cooper S, Gostkowski M, Rudolph J, Appleby K, Sweeney P, Fernandez HH. Oravivattanakul S, et al. Among authors: appleby k. Mov Disord Clin Pract. 2015 Oct 28;3(1):31-35. doi: 10.1002/mdc3.12261. eCollection 2016 Jan-Feb. Mov Disord Clin Pract. 2015. PMID: 30363515 Free PMC article.
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.
Munro APS, Feng S, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, Bula M, Cathie K, Chatterjee K, Dodd K, Enever Y, Qureshi E, Goodman AL, Green CA, Harndahl L, Haughney J, Hicks A, van der Klaauw AA, Kanji N, Libri V, Llewelyn MJ, McGregor AC, Maallah M, Minassian AM, Moore P, Mughal M, Mujadidi YF, Holliday K, Osanlou O, Osanlou R, Owens DR, Pacurar M, Palfreeman A, Pan D, Rampling T, Regan K, Saich S, Bawa T, Saralaya D, Sharma S, Sheridan R, Thomson EC, Todd S, Twelves C, Read RC, Charlton S, Hallis B, Ramsay M, Andrews N, Lambe T, Nguyen-Van-Tam JS, Snape MD, Liu X, Faust SN; COV-BOOST study group. Munro APS, et al. Lancet Infect Dis. 2022 Aug;22(8):1131-1141. doi: 10.1016/S1473-3099(22)00271-7. Epub 2022 May 9. Lancet Infect Dis. 2022. PMID: 35550261 Free PMC article. Clinical Trial.
25 results